Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 17497
Country/Region: Zambia
Year: 2015
Main Partner: University of Maryland
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $9,275,371 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $400,000
Care: TB/HIV (HVTB) $150,000
Care: Pediatric Care and Support (PDCS) $290,000
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Testing: HIV Testing and Counseling (HVCT) $775,371
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $2,650,000
Treatment: Adult Treatment (HTXS) $4,600,000
Treatment: Pediatric Treatment (PDTX) $410,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,196
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,196
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 635
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 1,561
PMTCT_ARV Sum of New and Current disaggregates 2016 2,196
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 78
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 31
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 109
PMTCT_EID Sum of Infant Age disaggregates 2016 109
PMTCT_STAT By: Known positives at entry 2016 2,346
PMTCT_STAT By: Number of new positives identified 2016 3,673
PMTCT_STAT Number of new ANC and L&D clients 2016 61,394
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 61,267
PMTCT_STAT Sum of Positives Status disaggregates 2016 6,019
TX_CURR Age/Sex: <1 Female 2016 21
TX_CURR Age/Sex: <1 Male 2016 21
TX_CURR Age/Sex: 1-4 Female 2016 40
TX_CURR Age/Sex: 1-4 Male 2016 32
TX_CURR Age/Sex: 5-14 Male 2016 2
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 2,185
TX_CURR Sum of Age/Sex disaggregations 2016 2,183
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 2,072
TX_NEW By Age/Sex: 20-24 Female 2016 1
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 1
TX_NEW Sum of Age/Sex disaggregates 2016 1